Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
US healthcare spending soars to over $5 trillion in 2024 - 2Barry Manilow reveals lung cancer diagnosis and plans to undergo surgery: 'It's pure luck' it was 'found so early'
- 3Unwind: Four Extraordinary Spa Resorts On the planet
- 4Scientist turns people’s mental images into text using ‘mind-captioning’ technology
- 5The most effective method to Involve Handshakes for Compromise and Compromise
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- Find the Native Culinary Customs: Local Flavors
- Ober Gabelhorn glacier reveals remains of man missing for over three decades
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- This cafe takes orders in sign language. It's cherished by the Deaf community
- New movies to watch this weekend: See 'Predator: Badlands' in theaters, rent 'Black Phone 2,' stream Guillermo del Toro's 'Frankenstein' on Netflix
- The Best Games On the planet
- Last supermoon of the year, the cold moon, seen across the U.S.: See the photos
- Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
